SNGX - Soligenix Inc. logo

Soligenix Inc.

SNGX

Soligenix Inc. develops biopharmaceutical products for rare diseases, focusing on cutaneous T-cell lymphoma and inflammatory conditions. It also creates vaccines for biodefense and infectious diseases, such as ricin exposure and COVID-19.

โš•๏ธ Healthcare NASDAQ Listed 1987 $ USD
$1,000 invested 30 years ago โ†’$0today

Score Overview

1 Year
Scoreโ€”
Net Growth7.59%
Net TrendGrew
Net Income Consistencyโ€”
Rev Growthโ€”
Rev TrendShrank
Revenue Consistencyโ€”
5 Years
Score3.7
Net Growth18.42%
Net Trend40%
Net Income Consistencyโ€”
Rev Growth-100.00%
Rev Trend40%
Revenue Consistencyโ€”
10 Years
Score
Net Growth-215.55%
Net Trend30%
Net Income Consistency
Rev Growth-100.00%
Rev Trend20%
Revenue Consistency
20 Years
Score2.3
Net Growth-25.44%
Net Trend40%
Net Income Consistency
Rev Growth-100.00%
Rev Trend45%
Revenue Consistency
30 Years
Scoreโ€”
Net Growth-422.42%
Net Trend40%
Net Income Consistency
Rev Growthโ€”
Rev Trend48%
Revenue Consistency
All Time
Scoreโ€”
Net Growth-6x
Net Trend39%
Net Income Consistency
Rev Growthโ€”
Rev Trend48%
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where Soligenix Inc. has ranked, year by year

Measure
Fundamentals Window

Showing 1 year ranking history by HDB Score.

Has not reached the top 50 on HDB Score in any year we have ranked.

  • SNGX

2005: 78.4% ยท 2021: 88.2% ยท free through 2021 ยท longest runs

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-09-30
$ 0.36โ€”
1 Year2025-09-30
$ 1.16-68.79%
5 Years2021-09-30
$ 254.40-99.86%
10 Years2016-09-30
$ 1.85K-99.98%
20 Years2006-09-29
$ 12.96K-100.00%
30 Years1996-09-30
$ 1000K-100.00%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 0.00-$ 10M$ 9M
2025$ 0.00-$ 11M$ 7M
2024$ 119.37K-$ 8M$ 7M
2023$ 839.36K-$ 6M$ 8M
2022$ 250K-$ 13M$ 13M
2021$ 33.35K-$ 12M$ 26M
2020$ 1M-$ 17M$ 18M
2019$ 3M-$ 9M$ 5M
2018$ 5M-$ 8M$ 8M
2017$ 5M-$ 7M$ 7M
2016$ 10M-$ 3M$ 8M
2015$ 8M-$ 7M$ 4M
2014$ 7M-$ 6M$ 5M
2013$ 3M-$ 10M$ 5M
2012$ 3M-$ 4M$ 3M
2011$ 7M-$ 2M$ 5M
2010$ 1M-$ 7M$ 7M
2009$ 2M-$ 6M$ 7M
2008$ 2M-$ 3M$ 1M
2007$ 1M-$ 6M$ 2M
2006$ 2M-$ 8M$ 119.64K
2005$ 3M-$ 4M$ 821.7K
2004$ 997.48K-$ 5M$ 2M
2003$ 83.82K-$ 5M$ 4M
2002-$ 4M$ 4M
2001-$ 14M$ 9M
2000-$ 4M$ 12M
1999-$ 7M$ 8M
1998-$ 21M$ 12M
1997-$ 3M$ 15M
1996-$ 1M
1995-$ 1M$ 1M
SNGX - Soligenix Inc. logo

Soligenix Inc. fundamental performance

Between 2020 and 2025, revenue declined from $ 1M to $ 0.00 and net income went from -$ 17M to -$ 11M. Revenue increased in 2 of those 5 years; net income in 2.

Between 2005 and 2025, revenue declined from $ 3M to $ 0.00 and net income went from -$ 4M to -$ 11M. Revenue increased in 9 of those 20 years; net income in 8.

Soligenix Inc. currently holds a 20-year HDB Score of 2.3 out of 10. How the HDB Score is calculated.

Membership

Continue SNGXโ€™s history

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 3,814 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year ยท Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies